secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001437749-23-021927
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO reports Q2 2023 net loss of $19.6M; receives $90M milestone from Pfizer for NGENLA approval
--------------------------------------------------------------------------------

- Consolidated revenue $265.4M, down from $309.9M YoY; operating income $7.0M vs loss of $10.7M.
- Pharma segment revenue rose to $43.5M; $94.9M IP transfer revenue included $90M NGENLA milestone.
- Diagnostics revenue fell to $127.0M from $186.8M due to lower COVID-19 testing volume and reimbursement.
- Cash and equivalents $108.1M, excluding the $90M milestone payment expected in August 2023.
- NGENLA approved in 44 markets; profit sharing with Pfizer begins from August 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/0001437749-23-021927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/opk20230712_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer